Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Cancer02:18

Cancer

51.6K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Frontiers in oncology·2026
Same author

Precision neuro-oncology for children: Time to gear up!

Trends in cancer·2026
Same author

Correction: Conditional generation of free radicals by selective activation of alkoxyamines: towards more effective and less toxic targeting of brain tumors.

Chemical science·2026
Same author

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Frontiers in oncology·2026
Same author

Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.

Targeted oncology·2026
Same author

Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same journal

Patient value over patent value: the mandate for open-source oncology.

Nature reviews. Clinical oncology·2026
Same journal

Cancer burden and control in China: landscape, trends and challenges.

Nature reviews. Clinical oncology·2026
Same journal

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Nature reviews. Clinical oncology·2026
Same journal

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer.

Nature reviews. Clinical oncology·2026
Same journal

Teclistamab monotherapy improves survival in RRMM.

Nature reviews. Clinical oncology·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Metronomics: towards personalized chemotherapy?

Nicolas André1, Manon Carré2, Eddy Pasquier3

  • 1Service d'Hématologie & Oncologie Pédiatrique, AP-HM, 264 rue Saint Pierre, 13385 Marseille, France.

Nature Reviews. Clinical Oncology
|June 11, 2014
PubMed
Summary
This summary is machine-generated.

Metronomic chemotherapy, an antiangiogenic therapy, has evolved with new insights into its immune-boosting and direct cancer cell effects. Recent clinical trials show its increasing combination with other treatments for personalized medicine.

More Related Videos

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.5K
Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine
06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

1.2K

Related Experiment Videos

Last Updated: Apr 28, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.5K
Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine
06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

1.2K

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Metronomic chemotherapy, established in 2000, is an antiangiogenic therapy.
  • Recent discoveries highlight its pro-immune properties and direct effects on cancer cells, revealing its multitargeted nature.

Purpose of the Study:

  • To review advances in metronomic chemotherapy.
  • To discuss its mechanisms, resistance factors, and clinical applications.

Main Methods:

  • Literature review of clinical trials and studies.
  • Analysis of recent data in adult and pediatric populations.
  • Discussion of ongoing clinical trials and future directions.

Main Results:

  • Significant rise in clinical trials over the past decade.
  • Increasing combination with conventional and novel therapies (chemotherapy, radiotherapy, targeted agents, immunotherapy).
  • Identification of factors contributing to disease resistance.

Conclusions:

  • Metronomic chemotherapy is a versatile therapeutic approach with evolving mechanisms.
  • Its combination strategies and role in personalized medicine are expanding.
  • Future developments hold promise for optimizing cancer treatment.